Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update
Globe Newswire•11/11/2026•16:01 ET
2
Key Highlights
- ➤Net profit €13.9M versus €461.3M loss in nine months 2025
- ➤Year-end cash guidance €2.0–€2.05B, including second €50M repurchase
- ➤Gamgertamig expected to enter registrational studies in 2027
- ➤Early-stage cell therapy pipeline sold for €8M upfront plus up to $230M milestones
- ➤Gamgertamig receives FDA Orphan Drug Designation for pemphigus
Expert Statements
Henry Gosebruch, Chief Executive Officer of Lakefront
“At ASH, we look forward to sharing results from patients enrolled in company-sponsored trials, which we believe will further characterize the differentiated efficacy and safety profile of gamgertamig and its potential as a first- and best-in-class T-cell engager in autoimmune disease”
Aaron Cox, Chief Financial Officer of Lakefront
“Our guidance for year-end 2026 cash and financial investments is at least €2 billion, including the recently completed share repurchase program and taking into account the decision to initiate a second €50 million share repurchase program, which is expected to be completed by the end of the first quarter of 2027”
Gamgertamig poster accepted for presentation at the 2026 ASH(1) Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”
Year-end 2026 guidance for cash and financial investments of at least €2B, including initiating a second €50M share repurchase program
Get started
Create a free account to read the full story.